Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis

• Status: Completed
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole groups. There were 24 subjects who finished the study, 13 from PTU group and 11 from methimazole group. Blood serum was collected for HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin examination. Meanwhile stiffness and thickness of carotid artery was measured using PWV and cIMT.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University
• Treatments: Methimazole; Propylthiouracil

Criteria

Inclusion Criteria:

• Adult patients aged 18-65 years

• Newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month

• Agreed to participate in the study

Exclusion Criteria:

• Pregnancy

• History of coronary heart disease

• Known malignancy

• Current use of immunosuppressive medication sepsis, thyroid crisis

• Having allergic reaction to anti-thyroid drugs and other severe side effect